Amdocal^? (5mg &10mg tablet) is the besylate salt of amlodipine, a long-acting calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle selectively, with a greater effect on vascular smooth muscle cells than on cardiac muscle cells. Amdocal^? is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents. Amdocal^? is indicated for the symptomatic treatment of chronic stable angina alone or in combination with other antianginal agents. In patients with recently documented CAD by angiography and without heart failure or an ejection fraction <40%, Amdocal is indicated to reduce the risk of hospitalization due to angina and to reduce the risk of a coronary revascularization procedure

Amlodipine is combined with atenolol (selective beta-blocker) for achieving goal BP in severe hypertension when monotherapy fails. Thus it ensures effective BP control in all hypertensive conditions, offers additive effects in angina and ensures lesser incidences of side effects

The combination of Amlodipine and Benazepril is used to treat high blood pressure. Benazepril has an antihypertensive effect even in patients with low-renin hypertension. Amlodipine inhibits calcium ion influx across cell membranes selectively, with a greater effect on vascular smooth muscle cells than on cardiac muscle cells. Amlodipine is a peripheral arterial vasodilator that acts directly on vascular smooth muscle to cause a reduction in peripheral vascular resistance and reduction in blood pressure. The antihypertensive effect of a single dose persisted for 24 hours. Once-daily doses of Benazepril/Amlodipine using Benazepril doses of 10-20 mg and Amlodipine doses of 2.5-10 mg decreased seated pressure (systolic/diastolic) 24 hours after dosing by about 10-25/6-13 mmHg.

It is a combination product containing Amlodipine Besilate BP equivalent to 5 mg Amlodipine, a calcium channel blocker and Atorvastatin calcium INN equivalent to 10 mg Atorvastatin, a statin (HMG-CoA reductase inhibitor). Amlodipine is a peripheral arterial vasodilator that acts directly on vascular smooth muscle to cause a reduction in peripheral vascular resistance and reduction in blood pressure. Atorvastatin calcium is a synthetic lipid-lowering agent. It is an inhibitor of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA). This enzyme catalyzes the conversion of HMG-CoA to mevatonate, an early and rate limiting step in the synthesis of cholesterol.

Arbit^? (Irbesartan) is an angiotensin II receptor (AT1 subtype) antagonist antihypertensive drug. Arbit^? (Irbesartan) is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.

Atova^?(atorvastatin calcium) is used in patients with multiple risk factors for the heart disease such as familial history, high blood pressure, age, low HDL or smoking, to reduce the risk of heart attack and stroke and along with a low-fat die, to lower cholesterol. It is also used in patients with type 2 diabetes and at least one other risk factor for heart disease such as high blood pressure, smoking or complication of diabetes, including eye diseases and protein in urine, to reduce the risk of heart attack and stroke.Atova^? is not for every one. It is not for those with liver problems. and it is not for woman who are nursing, pregnant or may become pregnant.

Atova® (Atorvastatin calcium) is a synthetic lipid-lowering agent. It is an inhibitor of 3- hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA). This enzyme catalyzes the conversion of HMG-CoA to mevatonate, an early and rate limiting step in the synthesis of cholesterol.

Betapro^? (Celiprolol Hydrochloride) is a ?-adrenoceptor blocker with selective ?1 antagonist, partial ?2 agonist, mild a2 antagonist and direct smooth muscle relaxant actions, but no quinidine like membrane stabilizing properties. The main therapeutic use of Betapro^? is in the management of hypertension and effort induced angina. Betapro^? (Celiprolol Hydrochloride) is indicated for mild to moderate hypertension and angina pectoris.

Bizoran® is a combination product containing Amlodipine, a calcium channel blocker and Olmesartan, an angiotensin II receptor blocker. Amlodipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle & cardiac muscle. Amlodipine is a peripheral arterial vasodilator that acts directly on vascular smooth muscle to cause a reduction in peripheral vascular resistance & a reduction in blood pressure. Olmesartan is an angiotensin II receptor blocker that acts on AT1 subtype. By blocking the action of angiotensin II, Olmesartan dilates blood vessels and reduces blood pressure without affecting pulse rate.

Cardopril^? contains Captopril which is the first of a new class of antihypertensive agents, a highly specific competitive inhibitor of angiotensin I converting enzyme. Cardopril^? is indicated in the treatment of the followings: Hypertension: Mild to moderate hypertension as an adjunct to thiazide therapy in patients who have not responded effectively to thiazide treatment alone. Severe hypertension: Where standard therapy has failed. Cardopril^? is effective alone or in combination with other antihypertensive agents especially thiazide type of diuretics. The blood pressure lowering effect of Cardopril^? and thiazides are approximately additive. Congestive heart failure: It is also used as an adjunct to the treatment of severe congestive heart failure.

Dilapress^? is a preparation of Carvedilol which is a cardiovascular drug acts mainly as neurohormonal antagonist consisting of non-selective ? blockade, a1 blockade and antioxidant properties. Dilapress^? reduces the risk of mortality. It also offers superior efficacy and safety in angina pectoris. Moreover it can be chosen as a drug for hypertensive patients with type 2 diabetes. It can be used alone or in combination with thiazide type of diuretics. Dilapress may be used in patients unable to tolerate an ACE inhibitor.

Enaril^? is preparation of enalapril which is used alone or in combination with other medications to treat high blood pressure. It is also used in combination with other medications to treat heart failure. Enalapril is in a class of medications called angi

Ezeta^? (Ezetimibe) is a medicine used to lower levels of total cholesterol and LDL (bad) cholesterol in the blood. It is used for patients who cannot control their cholesterol levels by diet alone. It can be used by itself or with other medicines to treat high cholesterol. Patient should stay on a cholesterol-lowering diet while taking this medicine. EZETA^? works to reduce the amount of cholesterol your body absorbs. EZETA^? does not help you lose weight. Do not take EZETA^? if you are allergic to ezetimibe, the active ingredient in EZETA^?, if you have active liver disease or ?If you are pregnant or breast-feeding. Take EZETA^? once a day, with or without food. It may be easier to remember to take your dose if you do it at the same time every day, such as with breakfast, dinner, or at bedtime. If you also take another medicine to reduce your cholesterol, ask your doctor if you can take them at the same time.

Fibril^? containing Gemfibrozil is an antilipemic agent Gemfibrozil decreases serum triglycerides in healthy individuals and in patients with hypertriglyceridemia. It decreases very low density lipoprotein (VLD)-triglyceride concentration. HDL-triglyceride is usually decreases slightly. Gemfibrozil usually increases the HDL-cholesterol fraction in healthy individuals and in patients with hyperlipoproteinemia, an action that may be beneficial in slowing the progression of atherosclerosis and in reducing the risk of coronary heart disease. Fibril^? is used as a hypolipidaemic agent in conjunction with dietary modification. The usual dose, by mouth is 1.2 g daily in 2 divided doses given 30 minutes before morning and evening meal. The dosage range may vary between 0.9-1.5 g daily or as advised by the physician.

Induric^? Plus is a combination of Perindopril Erbumine BP 2 mg & Indapamide USP 0.625 mg tablet. Induric^? Plus is the first very-low-dose combination indicated first-line in hypertension, is spearheading a radically new strategy in its management. This new approach provides a multifocal approach to the treatment of hypertension, responding to the need for better BP control, and in keeping with the multifactorial origin of hypertension. Induric^? Plus is indicated for the management of Essential hypertension.

Lofat^? (Fenofibrate) is a fibric acid derivative approved by the Food and Drug Administration in February of 1998 for the treatment of hyperlipidemia. Lofat^? (Fenofibrate) limits the availability of fatty acids for triglyceride synthesis within the liver, increases lipoprotein lipase activity, stimulates reverse cholesterol transport and suppresses activity of HMG-CoA reductase within the liver. Lofat^? (Fenofibrate) is indicated as an adjunct to diet for the treatment of adults with hyper-triglyceridemia (types IV and V hyperlipidemia) who have not responded adequately to diet therapy and who are at risk for pancreatitis. Lofat^? (Fenofibrate) is also indicated in mixed hyperlipidemia (types II hyperlipidemia).

Lonet^? is a beta-1 selective adrenoreceptor blocking agent .Lonet^? is indicated in hypertension, angina pectoris, acute myocardial infarction and cardiac arrythmias.

Neocard^? is a calcium antagonist. It is indicated for the prophylaxis and treatment of classical and vasospastic angina pectoris and hypertension, myocardial infarction, coronary artery spasm, hypertension, cardiac arrhythmias, Raynaud?s phenomenon, oesophagal motility disorder, and migraine.

Neopril^? is a preparation of Lisinopril, which is in a class of drugs called angiotensin-converting-enzyme (ACE) inhibitors. Neopril^? is used to lower blood pressure, to treat congestive heart failure, and to improve the survival rate after a heart attack

Nitrosol^? contains the active ingredient Glyceryl trinitrate, used to enable the heart to work more easily. Glyceryl trinitrate works by releasing a chemical called nitric oxide. This chemical is also made naturally by the body and has the effect of making the veins and arteries relax and widen (dilate). This increases the space within the blood vessels and therefore reduces the resistance within the blood vessels, which makes it easier for the heart to pump blood around the body.

Widening the veins also decreases the volume of blood that returns to the heart in the veins with each heartbeat, and this makes it easier for the heart to pump that blood out again. As a result of both these actions, the heart requires less energy to pump the blood around the body and therefore does not need as much oxygen.

Nitrosol^? is taken as a spray that is sprayed under the tongue. This area of the mouth has a large supply of blood vessels that allows the medicine to be rapidly absorbed. Glyceryl trinitrate taken in this way is used to give rapid relief from an angina attack, and can also be used to prevent an anticipated attack, for example before exercise.

Odrel^? (Clopidogrel) is an inhibitor of ADP-induced platelet aggregation acting by direct inhibition of adenosine diphosphate (ADP) binding to its receptor and of the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. Each tablet contains Clopidogrel Bisulfate INN equivalent to 75 mg Clopidogrel. Odrel^? (Clopidogrel) is indicated for the reduction of atherosclerotic events (myocardial infarction, stroke and vascular death) in patients with atherosclerosis documented by recent stroke, recent myocardial infarction or established peripheral arterial disease.

Odrel^?Plus is a fixed dose combination containing Clopidogrel and Aspirin.Clopidogrel is an inhibitor of platelet aggregation. Clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet receptor and the subsequent ADP-mediated activation of the glycoprotein GP Complex, thereby inhibiting platelet aggregation.Aspirin is also an antiplatelet agent. It acts by causing irreversible inhibition of the cyclo-oxygenase enzyme, which leads to decreased formation of thromboxane A2. Since platelets do not synthesise new enzyme, the action of Aspirin on platelet cyclo-oxygenase is permanent, lasting for the life of the platelets (7-10 days).Odrel^?Plus is indicated for the prevention of ischemic events, myocardial infarction, stroke and cardiovascular death in-patients what acute coronary syndrome.

It is a combination of an angiotensin II receptor antagonist (AT1 subtype), olmesartan medoxomil, and a thiazide diuretic, hydrochlorothiazide (HCTZ). Olmesartan medoxomil, a prodrug, is hydrolyzed to olmesartan during absorption from the gastrointestinal tract.

Pacet^? (Amiodarone) is a benzofuran derivative with an iodine content of nearly 40%. Its anti-anginal effect is based on the dilation of the coronary arteries; it reduces the peripheral vascular resistance, and is an antiarrhythmic agent for dysrhythmias of atrial and ventricular origin. It influences all the electrophysiologically important parts of the heart; it thus especially prolongs the action potential and refractory period of myocardial tissues and the atrioventricular conduction time. In comparison with other antiarrhythmic agents amiodarone possesses fewer arrhythmogenic effects.

Primace^? (Ramipril) is an angiotensin converting enzyme (ACE) inhibitor, which after hydrolysis to ramiprilat, blocks the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. So, inhibition of ACE by ramipril results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and decreased aldosterone secretion. Thus ramipril exerts its antihypertensive activity. It is also effective in the management of heart failure and reduction of the risk of stroke, myocardial infarction and death from cardiovascular events. It also reduces the risk of new diagnosis of diabetes. It is long acting and well tolerated, so, can be used in long term therapy. Primace^? is indicated in Mild to severe hypertension, Heart failure, To reduce the risk of stroke, myocardial infarction and death from cardiovascular events in patients with a history of cardiovascular disease.

Prosan^? (Losartan Potassium) is an angiotensin-II receptor (type AT1) antagonist. Losartan and its principal active metabolite block the vasoconstrictor and aldosterone secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor found in many tissues.It is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.

Prosan^? HZ(Losartan Potassium & Hydrochlorothiazide) is a combination product of Losartan Potassium and Hydrochlorothiazide. Losartan and its principal active metabolite block the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor found in many tissues, (e.g. vascular smooth muscle, adrenal gland). Hydrochlorothiazide is a thiazide diuretic which affects the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts. Prosan^? HZ is indicated for the treatment of hypertension. This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients.

Resitone^? is a combination of a potassium sparing diuretic, Spironolactone and a loop diuretic, Frusemide blocks the reabsorption of sodium, potassium and chloride ions thereby increases the quantity of sodium and the volume of water excreted in the urine. Spironolactonein inhibits the reabsorption of sodium and excretion of potassium. So the excretion of sodium is increased and the excess loss of potassium , induced by Frusemide is decreased. Resitone^? is indicated for the treatment of Oedema, Congestive heart failure, Liver cirrhosis with astices, Essential hypertension and Hyperaldosteronism.

Valcap^? (valsartan) is an angiotensin ll receptor antagonist with antihypertensive activity. It is nor the treatment of hypertension. The recommended dose of Valcap^? is 80 mg once daily, irrespective of race, age, or gender. The antihypertensive effect is substantially achieved within 2 weeks and maximal effects are seen after 4 weeks. In patients whose blood pressure is not adequately controlled, the daily dose may be increased to 160 mg or a diuretic may be added. No dosage adjustment is required for patients with renal impairment or for patients with hepatic insufficiency of non-biliary origin and without cholestasis. Valcap^? may also be administered with other antihypertensive agents.